Relay Therapeutics (RLAY) Receivables - Net (2020 - 2023)

Relay Therapeutics (RLAY) has 4 years of Receivables - Net data on file, last reported at $211000.0 in Q3 2023.

• Receivables - Net for Q3 2023 came in at $211000.0, down 12.45% year-over-year; the trailing twelve-month figure through Sep 2023 was $211000.0 (down 12.45% YoY), and the FY2022 annual result was $306000.0, down 24.07% from the prior year.
• Receivables - Net grew to $211000.0 in Q3 2023 per RLAY's latest filing, from $78000.0 in the prior quarter.
• Over five years, Receivables - Net peaked at $75.0 million in Q4 2020 and troughed at $78000.0 in Q2 2023.
• A 4-year average of $7.1 million and a median of $286000.0 in 2023 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2021 and 2023: Receivables - Net plunged 99.46% in 2021, then climbed 6.32% in 2023.
• A 4-year view of Receivables - Net shows it stood at $75.0 million in 2020, then sank by 99.46% to $403000.0 in 2021, then fell by 24.07% to $306000.0 in 2022, then plunged by 31.05% to $211000.0 in 2023.
• Business Quant data shows RLAY's Receivables - Net at $211000.0 in Q3 2023, $78000.0 in Q2 2023, and $286000.0 in Q1 2023.